DIAGNOSTIC ACCURACY OF AMYLOID- VERSUS FDG-PET IN AUTOPSY-CONFIRMED DEMENTIA

[1]  B. Miller,et al.  Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.

[2]  Gil D Rabinovici,et al.  Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample , 2017, Neurology.

[3]  Daniel R. Schonhaut,et al.  Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease , 2017, Brain : a journal of neurology.

[4]  William J. Jagust,et al.  Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease , 2017, NeuroImage.

[5]  L. Grinberg,et al.  Neuropathological diagnoses and clinical correlates in older adults in Brazil: A cross-sectional study , 2017, PLoS medicine.

[6]  Alan J. Thomas,et al.  Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB , 2017, Neurology.

[7]  Sang Won Seo,et al.  Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort , 2016, NeuroImage: Clinical.

[8]  Gereon R. Fink,et al.  Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease , 2016, Annals of clinical and translational neurology.

[9]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[10]  James M. Mountz,et al.  Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects , 2015, NeuroImage: Clinical.

[11]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[12]  Karen M Rodrigue,et al.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.

[13]  Clifford R. Jack,et al.  Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.

[14]  Ranjan Duara,et al.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.

[15]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[16]  Miranka Wirth,et al.  Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions , 2014, Neurology.

[17]  N. Bohnen,et al.  Brain PET in suspected dementia: patterns of altered FDG metabolism. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.

[18]  L. Thurfjell,et al.  Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Cindee M. Madison,et al.  Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  Cindee M. Madison,et al.  The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction. , 2013, JAMA neurology.

[21]  Keith A. Johnson,et al.  Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association , 2013, The Journal of Nuclear Medicine.

[22]  Cindee M. Madison,et al.  Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. , 2013, Brain : a journal of neurology.

[23]  Peter Herscovitch,et al.  Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association , 2013, Alzheimer's & Dementia.

[24]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[25]  M. Pontecorvo,et al.  Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[27]  C. Rowe,et al.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[29]  J. Kornak,et al.  Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .

[30]  S. Black,et al.  Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[31]  E. Steyerberg,et al.  [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.

[32]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[33]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[34]  W. M. van der Flier,et al.  Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[35]  E. Huang,et al.  Sporadic corticobasal syndrome due to FTLD-TDP , 2010, Acta Neuropathologica.

[36]  John Q. Trojanowski,et al.  Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update , 2009, Acta Neuropathologica.

[37]  M. Aminoff,et al.  Seizures in corticobasal degeneration: A case report , 2009, Neurocase.

[38]  B. Miller,et al.  Neurodegenerative Diseases Target Large-Scale Human Brain Networks , 2009, Neuron.

[39]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[40]  Margaret Sullivan Pepe,et al.  Estimating the capacity for improvement in risk prediction with a marker. , 2008, Biostatistics.

[41]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[42]  C. DeCarli,et al.  What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? , 2007, Neurology.

[43]  Christopher C Rowe,et al.  Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease , 2007, Journal of Nuclear Medicine.

[44]  J. Cummings,et al.  Early-Onset Alzheimer’s Disease Is Associated With Greater Pathologic Burden , 2007, Journal of geriatric psychiatry and neurology.

[45]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[46]  Jennifer Farmer,et al.  Frontotemporal dementia: Clinicopathological correlations , 2006, Annals of neurology.

[47]  John Hodges,et al.  Pathologically proven frontotemporal dementia presenting with severe amnesia. , 2005, Brain : a journal of neurology.

[48]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[49]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[50]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[51]  M. Pepe,et al.  Comparisons of Predictive Values of Binary Medical Diagnostic Tests for Paired Designs , 2000, Biometrics.

[52]  K Patterson,et al.  Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. , 2000, Brain : a journal of neurology.

[53]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[54]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[55]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.